Bray Capital Advisors’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $557K | Hold |
4,250
| – | – | 0.15% | 92 |
|
|
2024
Q3 | $662K | Hold |
4,250
| – | – | 0.16% | 90 |
|
|
2024
Q2 | $663K | Hold |
4,250
| – | – | 0.17% | 89 |
|
|
2024
Q1 | $576K | Hold |
4,250
| – | – | 0.15% | 96 |
|
|
2023
Q4 | $572K | Hold |
4,250
| – | – | 0.16% | 96 |
|
|
2023
Q3 | $576K | Hold |
4,250
| – | – | 0.18% | 94 |
|
|
2023
Q2 | $608K | Hold |
4,250
| – | – | 0.18% | 95 |
|
|
2023
Q1 | $590K | Hold |
4,250
| – | – | 0.17% | 99 |
|
|
2022
Q4 | $576K | Hold |
4,250
| – | – | 0.18% | 99 |
|
|
2022
Q3 | $466K | Hold |
4,250
| – | – | 0.15% | 106 |
|
|
2022
Q2 | $562K | Hold |
4,250
| – | – | 0.17% | 100 |
|
|
2022
Q1 | $564K | Hold |
4,250
| – | – | 0.14% | 103 |
|
|
2021
Q4 | $495K | Hold |
4,250
| – | – | 0.12% | 110 |
|
|
2021
Q3 | $511K | Hold |
4,250
| – | – | 0.13% | 107 |
|
|
2021
Q2 | $509K | Hold |
4,250
| – | – | 0.13% | 106 |
|
|
2021
Q1 | $423K | Hold |
4,250
| – | – | 0.12% | 109 |
|
|
2020
Q4 | $425K | Hold |
4,250
| – | – | 0.12% | 106 |
|
|
2020
Q3 | $466K | Hold |
4,250
| – | – | 0.16% | 98 |
|
|
2020
Q2 | $450K | Hold |
4,250
| – | – | 0.17% | 98 |
|
|
2020
Q1 | $380K | Hold |
4,250
| – | – | 0.17% | 95 |
|
|
2019
Q4 | $424K | Sell |
4,250
-500
| -11% | -$47.1K | 0.15% | 104 |
|
|
2019
Q3 | $423K | Hold |
4,750
| – | – | 0.17% | 99 |
|
|
2019
Q2 | $392K | Hold |
4,750
| – | – | 0.15% | 104 |
|
|
2019
Q1 | $384K | Sell |
4,750
-500
| -10% | -$39.4K | 0.16% | 106 |
|
|
2018
Q4 | $399K | Hold |
5,250
| – | – | 0.2% | 95 |
|
|
2018
Q3 | $415K | Hold |
5,250
| – | – | 0.18% | 94 |
|
|
2018
Q2 | $369K | Hold |
5,250
| – | – | 0.17% | 94 |
|
|
2018
Q1 | $367K | Hold |
5,250
| – | – | 0.17% | 92 |
|
|
2017
Q4 | $364K | Hold |
5,250
| – | – | 0.17% | 96 |
|
|
2017
Q3 | $356K | Hold |
5,250
| – | – | 0.19% | 91 |
|
|
2017
Q2 | $358K | Hold |
5,250
| – | – | 0.2% | 87 |
|
|
2017
Q1 | $327K | Sell |
5,250
-100
| -2% | -$5.82K | 0.19% | 85 |
|
|
2016
Q4 | $292K | Hold |
5,350
| – | – | 0.18% | 90 |
|
|
2016
Q3 | $352K | Hold |
5,350
| – | – | 0.21% | 83 |
|
|
2016
Q2 | $323K | Hold |
5,350
| – | – | 0.2% | 84 |
|
|
2016
Q1 | $301K | Hold |
5,350
| – | – | 0.26% | 68 |
|
|
2015
Q4 | $363K | Hold |
5,350
| – | – | 0.23% | 87 |
|
|
2015
Q3 | $340K | Hold |
5,350
| – | – | 0.22% | 92 |
|
|
2015
Q2 | $341K | Hold |
5,350
| – | – | 0.2% | 103 |
|
|
2015
Q1 | $366K | Sell |
5,350
-100
| -2% | -$6.95K | 0.22% | 102 |
|
|
2014
Q4 | $384K | Buy |
+5,450
| New | +$390K | 0.25% | 104 |
|
Other funds holding AZN
Bray Capital Advisors's AZN Position: Q4 2024 in Review
Bray Capital Advisors held its AstraZeneca (AZN) position steady in Q4 2024 at 4,250 shares worth $557K. The position accounts for 0.15% of the portfolio, ranked #92.
Bray Capital Advisors first reported a position in AZN in Q4 2014 and has held it in 41 quarters since. The position peaked at $663K in Q2 2024. 1,218 funds tracked by Wall St. Rank hold AZN as of Q4 2024.
- Bray Capital Advisors held 4,250 shares of AstraZeneca worth $557K as of Q4 2024.
- Bray Capital Advisors left its AstraZeneca share count unchanged in Q4 2024.
- AstraZeneca made up 0.15% of Bray Capital Advisors's portfolio in Q4 2024, its #92 holding.
- Bray Capital Advisors first reported a position in AstraZeneca in Q4 2014 and has held it in 41 quarters since.
- Bray Capital Advisors's AstraZeneca position peaked at $663K in Q2 2024.
- 1,218 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2024.
Based on Bray Capital Advisors's 13F filing for Q4 2024, filed 3 Feb 2025.